Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

Trial Profile

A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine/samidorphan (Primary) ; Bupropion
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms FORWARD-4
  • Sponsors Alkermes plc
  • Most Recent Events

    • 01 Feb 2019 According to an Alkermes media release, company received a complete response letter from the US FDA for its NDA for buprenorphine/samidorphan. The CRL stated that the US FDA was unable to approve the NDA in its present form and requested additional clinical data . Company plans to meet with the US FDA to discuss the contents of the CRL and potential next steps.
    • 01 Nov 2018 According to an Alkermes media release, the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the companys New Drug Application (NDA) for ALKS 5461. The committee jointly voted that the benefit-risk profile was not adequate to support approval (Vote: 2 Yes/ 21 No).
    • 01 Nov 2018 According to an Alkermes media release, the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), will meet today to review the New Drug Application (NDA) for ALKS 5461.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top